Literature DB >> 24314367

Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States.

Stanley H Hsia1, Monica L Desnoyers, Martin L Lee.   

Abstract

BACKGROUND: Across the United States, hyperlipidemia remains inadequately controlled and may vary across states according to differences in health insurance coverage and/or race/ethnicity.
OBJECTIVE: To examine relationships between states' health insurance and race/ethnicity characteristics with measures of hyperlipidemia management across the 50 U.S. states and the District of Columbia.
METHODS: Cross-validated, multiple linear regression modeling was used to analyze associations between states' health insurance patterns or proportions of racial minorities (from the 2010 U.S. Census data) and states' aggregate frequency of checking cholesterol within the previous 5 years or prescriptions written for lipid-lowering medications (from national survey and population-adjusted retail prescription data, respectively), with adjustments for age, sex, body mass index, race/ethnicity, and poverty.
RESULTS: In states with proportionately more uninsured, cholesterol levels are checked less often, but in states with proportionately more private, Medicare, or Medicaid coverage, providers are not necessarily more likely to check cholesterol or to write more prescriptions. In states with proportionately more African-Americans and/or Hispanics, cholesterol is more likely to be checked, but in states with more African-Americans, more prescriptions were written, whereas in states with more Hispanics, fewer statin prescriptions were written.
CONCLUSION: Variations across states in insurance and racial/ethnicity mix are associated with variations in hyperlipidemia management; less-insured states may be less effective whereas states with more private, Medicare, or Medicaid coverage may not be more effective. In states with proportionately more African-Americans vs. Hispanics, lipid medications may be prescribed differently. Our findings warrant further investigations.
Copyright © 2013 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholesterol screening; Ethnicity; HMG-CoA reductase inhibitors; Health insurance; Lipid lowering medications; Race

Mesh:

Substances:

Year:  2013        PMID: 24314367      PMCID: PMC3857541          DOI: 10.1016/j.jacl.2013.03.010

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  12 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance.

Authors:  Lakshmi Venkitachalam; Kaijun Wang; Avi Porath; Ramon Corbalan; Alan T Hirsch; David J Cohen; Sidney C Smith; E Magnus Ohman; Ph Gabriel Steg; Deepak L Bhatt; Elizabeth A Magnuson
Journal:  Circulation       Date:  2012-04-09       Impact factor: 29.690

Review 3.  Why do we still use stepwise modelling in ecology and behaviour?

Authors:  Mark J Whittingham; Philip A Stephens; Richard B Bradbury; Robert P Freckleton
Journal:  J Anim Ecol       Date:  2006-09       Impact factor: 5.091

4.  Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.

Authors:  Jon G Keevil; Michael W Cullen; Ronald Gangnon; Patrick E McBride; James H Stein
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

5.  State variation in Medicaid spending: hard to justify.

Authors:  John Holahan
Journal:  Health Aff (Millwood)       Date:  2007-09-18       Impact factor: 6.301

6.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Authors:  Michael H Davidson; Kevin C Maki; Thomas A Pearson; Richard C Pasternak; Prakash C Deedwania; James M McKenney; Gregg C Fonarow; David J Maron; Benjamin J Ansell; Luther T Clark; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2005-08-15       Impact factor: 2.778

7.  Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-02-04       Impact factor: 17.586

8.  Surveillance of certain health behaviors and conditions among states and selected local areas --- Behavioral Risk Factor Surveillance System, United States, 2009.

Authors:  Chaoyang Li; Lina S Balluz; Catherine A Okoro; Tara W Strine; Jin-Mann S Lin; Machell Town; William Garvin; Wilmon Murphy; William Bartoli; Balarami Valluru
Journal:  MMWR Surveill Summ       Date:  2011-08-19

Review 9.  Gender differences in health care expenditures, resource utilization, and quality of care.

Authors:  Gary M Owens
Journal:  J Manag Care Pharm       Date:  2008-04

10.  Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

Authors:  David D Waters; Carlos Brotons; Cheng-Wen Chiang; Jean Ferrières; JoAnne Foody; J Wouter Jukema; Raul D Santos; Juan Verdejo; Michael Messig; Ruth McPherson; Ki-Bae Seung; Lisa Tarasenko
Journal:  Circulation       Date:  2009-06-22       Impact factor: 29.690

View more
  7 in total

Review 1.  Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.

Authors:  Parth Shah
Journal:  Curr Cardiol Rep       Date:  2018-05-19       Impact factor: 2.931

2.  PCSK9 Inhibitors Show Value for Patients and the US Health Care System.

Authors:  Wei-Han Cheng; Étienne Gaudette; Dana P Goldman
Journal:  Value Health       Date:  2017-06-17       Impact factor: 5.725

3.  Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.

Authors:  Charles J Glueck; Parth Shah; Naila Goldenberg; Marloe Prince; Kevin Lee; Vybhav Jetty; Ashwin Kumar; Michael Goldenberg; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-03-12       Impact factor: 3.876

4.  Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.

Authors:  Parth Shah; Charles J Glueck; Vybhav Jetty; Naila Goldenberg; Matan Rothschild; Rashid Riaz; Gregory Duhon; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-08-18       Impact factor: 3.876

5.  Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.

Authors:  Vybhav Jetty; Charles J Glueck; Kevin Lee; Naila Goldenberg; Marloe Prince; Ashwin Kumar; Michael Goldenberg; Ishan Anand; Ping Wang
Journal:  Vasc Health Risk Manag       Date:  2017-07-06

6.  Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.

Authors:  Joshua Choi; Amir M Khan; Michael Jarmin; Naila Goldenberg; Charles J Glueck; Ping Wang
Journal:  Lipids Health Dis       Date:  2017-07-24       Impact factor: 3.876

7.  Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.

Authors:  Parth Shah; Charles J Glueck; Naila Goldenberg; Sarah Min; Chris Mahida; Ilana Schlam; Matan Rothschild; Ali Huda; Ping Wang
Journal:  Lipids Health Dis       Date:  2017-01-23       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.